Adlai Nortye has dosed the first patient in the intermittent weekly dosing arm of a global Phase 1 trial for AN9025 [1].
This development is critical because the pan-RAS(ON) inhibitor currently lacks human validation. The trial aims to generate the initial efficacy data necessary to determine if the drug provides a clinical benefit to patients [2].
AN9025 is designed as a pan-RAS(ON) inhibitor, targeting a protein family often implicated in various cancers. The current phase of the study focuses on the safety and tolerability of an intermittent weekly dosing schedule across multiple international sites [1].
While the start of dosing marks a transition from preclinical study to human testing, the timeline for results remains extended. Efficacy data for AN9025 will not be available until 2027 [2]. This gap means the drug remains in an early stage of development, where the primary goal is to establish a safe dose and observe early biological responses.
Industry analysts said the drug still requires significant human validation before it can move toward later-stage trials or regulatory approval. The global nature of the Phase 1 trial allows the company to gather data from a diverse patient population, though the long wait for efficacy results underscores the inherent risks of early-stage drug development [2].
“The drug still requires human validation.”
The transition to human dosing is a pivotal milestone for Adlai Nortye, but the 2027 timeline for efficacy data indicates that the drug is in a high-risk, high-reward stage. Because pan-RAS inhibitors target a challenging protein family, the success of this Phase 1 trial is the only way to prove that the theoretical benefits seen in labs translate to actual human patients.
